Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA; Department of Neuroscience, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA; Myosin Therapeutics, Jupiter, FL, USA.
Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA; Department of Neuroscience, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA.
Curr Opin Neurobiol. 2024 Aug;87:102898. doi: 10.1016/j.conb.2024.102898. Epub 2024 Aug 2.
Misuse and accidental overdoses attributed to stimulants are escalating rapidly. These stimulants include methamphetamine, cocaine, amphetamine, ecstasy-type drugs, and prescription stimulants such as methylphenidate. Unlike opioids and alcohol, there are no therapies approved by the US Food and Drug Administration (FDA) to treat stimulant-use disorder. The high rate of relapse among this population highlights the insufficiency of current treatment options, which are limited to abstinence support programs and behavioral modification therapies. Here, we briefly outline recent regulatory actions taken by FDA to help support the development of new stimulant use disorder treatments and highlight several new therapeutics in the clinical development pipeline.
由于兴奋剂的滥用和意外过量使用，其数量正在迅速增加。这些兴奋剂包括冰毒、可卡因、安非他命、摇头丸类药物和哌甲酯等处方兴奋剂。与阿片类药物和酒精不同，美国食品和药物管理局 (FDA) 尚未批准任何疗法来治疗兴奋剂使用障碍。在这些人群中，高复发率突出表明了当前治疗方案的不足，目前的治疗方案仅限于禁欲支持计划和行为修正疗法。在这里，我们简要概述了 FDA 最近采取的监管行动，以帮助支持新的兴奋剂使用障碍治疗方法的开发，并重点介绍了临床开发管道中的几种新疗法。
